Verastem Inc. reported preliminary, unaudited net product revenues of approximately $17.5 million for the fourth quarter of 2025 and about $30.9 million for the full year 2025, reflecting the launch of AVMAPKI™ FAKZYNJA™ CO-PACK in May following FDA approval. The company ended 2025 with preliminary cash, cash equivalents, and investments totaling $205 million, with a pro-forma year-end figure of $234 million after accounting for $29.4 million in net proceeds from the exercise of expiring cash warrants. Verastem expects its cash runway to extend into the first half of 2027. The company plans to release final fourth quarter and full year 2025 results during its earnings call in early March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.